These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 21612462)

  • 1. Eculizumab in severe Shiga-toxin-associated HUS.
    Lapeyraque AL; Malina M; Fremeaux-Bacchi V; Boppel T; Kirschfink M; Oualha M; Proulx F; Clermont MJ; Le Deist F; Niaudet P; Schaefer F
    N Engl J Med; 2011 Jun; 364(26):2561-3. PubMed ID: 21612462
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
    Mahat U; Matar RB; Rotz SJ
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27913. PubMed ID: 31286658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
    Ağbaş A; Göknar N; Akıncı N; Yıldırım ZY; Taşdemir M; Benzer M; Gökçe İ; Candan C; Küçük N; Uzuner S; Özçelik G; Demirkol D; Sever L; Çalışkan S
    Pediatr Nephrol; 2018 Dec; 33(12):2371-2381. PubMed ID: 30159625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Escherichia coli associated hemolytic and uremic syndrome: what lessons can be learned after the European epidemic of 2011?].
    Lemaignen A; Ridel C; Hertig A; Rondeau E
    Nephrol Ther; 2013 Jun; 9(3):129-36. PubMed ID: 23266201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
    Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
    Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome.
    Picard C; Burtey S; Bornet C; Curti C; Montana M; Vanelle P
    Pathol Biol (Paris); 2015 Jun; 63(3):136-43. PubMed ID: 25845294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review.
    de Zwart PL; Mueller TF; Spartà G; Luyckx VA
    Pediatr Nephrol; 2024 May; 39(5):1369-1385. PubMed ID: 38057431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of typical (enteropathic) hemolytic uremic syndrome.
    Bitzan M; Schaefer F; Reymond D
    Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
    Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
    Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.
    Delmas Y; Vendrely B; Clouzeau B; Bachir H; Bui HN; Lacraz A; Hélou S; Bordes C; Reffet A; Llanas B; Skopinski S; Rolland P; Gruson D; Combe C
    Nephrol Dial Transplant; 2014 Mar; 29(3):565-72. PubMed ID: 24293658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.
    Pape L; Hartmann H; Bange FC; Suerbaum S; Bueltmann E; Ahlenstiel-Grunow T
    Medicine (Baltimore); 2015 Jun; 94(24):e1000. PubMed ID: 26091445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemolytic uremic syndrome caused by Shiga-toxin-producing Escherichia coli].
    Loirat C
    Rev Prat; 2013 Jan; 63(1):11-6. PubMed ID: 23457821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
    Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
    Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?
    Mauras M; Bacchetta J; Duncan A; Lavocat MP; Rohmer B; Javouhey E; Collardeau-Frachon S; Sellier-Leclerc AL
    Pediatr Nephrol; 2019 Jul; 34(7):1289-1293. PubMed ID: 30963282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
    Giordano P; Netti GS; Santangelo L; Castellano G; Carbone V; Torres DD; Martino M; Sesta M; Di Cuonzo F; Resta MC; Gaeta A; Milella L; Chironna M; Germinario C; Scavia G; Gesualdo L; Giordano M
    Pediatr Nephrol; 2019 Mar; 34(3):517-527. PubMed ID: 30362078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hemolytic uremic syndrome.
    Loirat C; Saland J; Bitzan M
    Presse Med; 2012 Mar; 41(3 Pt 2):e115-35. PubMed ID: 22284541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome.
    Braune SA; Wichmann D; von Heinz MC; Nierhaus A; Becker H; Meyer TN; Meyer GP; Müller-Schulz M; Fricke J; de Weerth A; Hoepker WW; Fiehler J; Magnus T; Gerloff C; Panzer U; Stahl RA; Wegscheider K; Kluge S
    Crit Care Med; 2013 Jul; 41(7):1702-10. PubMed ID: 23660733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.